Hyoscine butylbromide in Chronic Kidney Disease Stage IV
Hyoscine butylbromide (Buscopan) 10 mg tablets are not listed as contraindicated specifically for chronic kidney disease (CKD) stage IV in the available European product information. [1] Use should be based on overall contraindications and anticholinergic risk assessment rather than CKD stage alone. [1]
Dosing in Renal Impairment
A renal dose adjustment schedule for hyoscine butylbromide 10 mg coated tablets is not specified in the available product information. [1] The product information supports dose use decisions driven by contraindications and precautions rather than CKD-specific dosing limits. [1]
Contraindications Relevant to CKD Stage IV
Hyoscine butylbromide is contraindicated in conditions that predispose to urinary retention and bowel obstruction, including: [1]
- Mechanical stenosis in the gastrointestinal tract. [1]
- Paralytic or obstructive ileus. [1]
- Megacolon. [1]
- Narrow angle glaucoma. [1]
- Myasthenia gravis. [1]
Precautions Relevant to CKD Stage IV
Anticholinergic complications should prompt caution in patients susceptible to intestinal or urinary outlet obstruction. [1] Urinary retention is a documented adverse reaction (rare). [1]
Medication Selection and Safety Monitoring
For patients receiving hyoscine butylbromide in CKD stage IV, safety monitoring should focus on: [1]
- Development of urinary retention symptoms, given urinary retention risk. [1]
- Anticholinergic adverse effects such as tachycardia and other anticholinergic complications, given anticholinergic class effects. [1]
- Appropriateness of treating the underlying indication, since the product advises avoiding continuous daily use without investigating the cause of abdominal pain. [1]
Practical Clinical Determination for Use
Administration of hyoscine butylbromide 10 mg three times daily can be considered in CKD stage IV when there is no relevant contraindication and when urinary outlet obstruction is not present or suspected. [1] If urinary outlet obstruction is present or if urinary retention develops, discontinuation and urgent reassessment are indicated. [1]
Key Adverse Effects to Anticipate
Urinary retention should be anticipated as a potential clinically significant adverse effect. [1] Tachycardia and other anticholinergic complications should be anticipated in susceptible patients. [1]